NeuroOne Medical Technologies Corporation (NMTC) Fair Value 2026

NMTC · Medical Devices · 2026-08-27

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, NeuroOne Medical Technologies Corporation (NMTC) trades at $1.98. QOC: 6.1/10. Value Trap Risk: 35/100 (LOW). 0/13 models active.

Key Facts

Ticker: NMTC
Price: $1.98
Quality Score: 6.1/10
Value Trap Risk: 35/100
Models Active: 0/13
Last Updated: 2026-08-27

Strength: 0 independent models provide multi-angle coverage

Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give NMTC?

0 Intrinsic Value Models vs. Current Price ($1.98)

Core Models (Unlocked)
Model	Fair Value	Upside

All Models Active

All 0 models are displayed above.

What Is NeuroOne Medical Technologies Corporation (NMTC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, NeuroOne Medical Technologies Corporation currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About NMTC?

0 of 13 models are currently active for NMTC. See which stocks rank higher →

How Does NMTC Rank in Medical Devices?

Among 157 Medical Devices stocks, NMTC ranks #88 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to pharmaceutical industry businesses. For NeuroOne Medical Technologies Corporation, metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is NMTC a Value Trap?

CirclFi's Value Trap algorithm assigns NMTC a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for NeuroOne Medical Technologies Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, NeuroOne Medical Technologies Corporation scores 6.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NMTC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy NeuroOne Medical Technologies Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

RPIDRapid Micro Biosystems, Inc.QOC 6.1 AIDX20/20 Biolabs, Inc.QOC 6.0 ENOVEnovis CorporationQOC 6.1 VYCOVycor Medical, Inc.QOC 6.0 BBNXBeta Bionics, Inc.QOC 6.1 SSIISS Innovations International, Inc.QOC 6.0 FEEDENvue Medical, Inc.QOC 4.8 INSPInspire Medical Systems, Inc.QOC 9.0 MASS908 Devices Inc.QOC 7.1 IRMDIRADIMED CORPORATIONQOC 9.8 PODDInsulet CorporationQOC 9.6

Read investment analysis: RPID · AIDX · ENOV · VYCO · BBNX · SSII · FEED · INSP · MASS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NMTC?

7 companies across all industries closest to NMTC’s Quality of Company score of 6.1/10.

NXPLNextPlat CorpQOC 6.1 SIDCompanhia Siderúrgica NacionalQOC 6.0 VODVodafone Group Public Limited CompanyQOC 6.1 RANDRand Capital CorporationQOC 6.0 IORIncome Opportunity Realty Investors, Inc.QOC 6.1 CHGGChegg, Inc.QOC 6.0 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NXPL · SID · VOD · RAND · IOR · CHGG · NVDA

Where Does NMTC Sit in CirclFi's Medical Devices Rankings?

NMTC is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About NeuroOne Medical Technologies Corporation’s Valuation?

What is NeuroOne Medical Technologies Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for NeuroOne Medical Technologies Corporation (NMTC). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NMTC overvalued or undervalued right now?

At $1.98, 0 of 0 active models suggest NMTC may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits NeuroOne Medical Technologies Corporation's business model in Medical Devices.

What does a Quality of Company score of 6.1 mean for NMTC?

NeuroOne Medical Technologies Corporation's QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NMTC?

CirclFi analyzes NMTC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is NMTC a value trap in 2026?

NeuroOne Medical Technologies Corporation's Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns NeuroOne Medical Technologies Corporation (NMTC) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/NMTC/ · Methodology

Primary sources for this NMTC valuation

Financial statements: NeuroOne Medical Technologies Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001500198) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NMTC as of 2026-08-27; valuations recomputed 2026-08-27.